A novel approach to the treatment of AD involves the inhibition of PDE4, an enzyme that degrades the intracellular second messenger cAMP and initiates the inflammatory cascade; cAMP‐dependent inhibition of PDE4 suppresses this inflammatory response 5, 6. Here, PDE4A is linked to Alzheimer disease.